As of 2025-11-18, the Fair Value of NextCell Pharma AB (NXTCL.ST) is -1.58 SEK. This value is based on the Peter Lynch's Fair Value formula. With the current market price of 0.79 SEK, the upside of NextCell Pharma AB is -298.68%.
With the market price of 0.79 SEK and our fair value calculation, NextCell Pharma AB (NXTCL.ST) is not a good investment. Investing in NXTCL.ST stocks now will result in a potential loss of 298.68%.
Note: valuation result may not be accurate due to the company's negative EPS.
Peter Lynch's formula is:
The earnings growth rate we use in the formula is the average growth rate of net income/earnings over the last 5 years. If the average growth rate is smaller than 5%, we set it to 5%. If it is larger than 25%, we set it to 25%. If the TTM EPS is negative, Peter Lynch Fair Value's result can be unreliable.
| Historical Earnings | ||||||
| 2021-08-31 | 2022-08-31 | 2023-08-31 | 2024-08-31 | 2025-08-31 | 5Y Avg | |
| Net income | -24.56 | -34.55 | -39.81 | -41.96 | -35.14 | -35.21 |
| YoY growth | -38.89% | -40.71% | -15.21% | -5.40% | 16.25% | -16.79% |
| Market Cap (mil) | 88.44 |
| P/E | |
| Forward P/E |
| EPS | -0.32 |
| Avg earnings growth rate | -16.79% |
| TTM earnings | -35.14 |